Format

Send to

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2012 Dec 13;367(24):2275-83. doi: 10.1056/NEJMoa1211107. Epub 2012 Nov 6.

Reduction in inappropriate therapy and mortality through ICD programming.

Collaborators (151)

Goldstein R, Haigney M, Oakes D, Dwyer E, Ehlert F, Lichstein E, Beck C, Bausch J, Hall WJ, McNitt S, Brown M, Andrews M, Barber D, Buermann R, Buttaccio A, Kremer K, Lansing R, Mykins B, Oberer A, Perkins E, Polonsky B, Pyykkonen K, Ramsell D, Zareba W, Goldenberg I, Klein H, Kutyifa V, Rosero S, Tompkins C, Moss A, Beck C, Brown M, Cannom D, Daubert J, Estes M, Greenberg H, Huang D, Kautzner J, Olshansky B, Schuger C, Shoda M, Wilber D, Gottlieb C, Swarup V, Greer S, Beau S, Whitehill J, Curnis A, Lunati M, Vernooy K, Khalameizer V, Cook J, Gandhi G, Sweeney M, Koplan B, Switzer D, Yesenosky G, Hessen S, Ludmer P, Stockburger M, Stockburger M, Boldt LH, Lande G, Feldman L, Thomas K, Hariharan R, Martin H, Rashtian M, Giudici M, Brewer R, Thomsen PB, Hojgaard M, Cannom D, Lai P, Schuger C, Vogt J, Okumura K, Kacet S, De La Concha JF, Kaab S, Marchlinski F, Coutu B, Varanasi S, Kautzner J, Padeletti L, Musco S, Sheehan C, Delnoy P, Goel S, Swissa M, Kuniss M, Ando K, Lessmeier T, Kimura T, Gohn D, Klein S, Santucci P, Singh J, Pieske B, Klein G, Oswald H, Shinn T, Meininger G, Kidwell G, Gornick C, Lobban J, Gross J, Coyne R, Kamakura S, Sandler D, Favale S, Nsah E, Dan D, Peress D, Boulos M, O'Neill G, Maleki K, Bedi M, Krishnan K, Athill C, Merkely B, Bernstein R, Medina A, Glikson M, Gottipaty V, Gauri A, Wilczek J, Pires L, Sharma N, Aziz E, Arshad A, Kushner J, Cox M, Le B, Geist M, Shoda M, Aonuma K, Link M, Weiner S, Schaer B, Kuschyk J, Mitchell L, Burke M, Rosenthal L, Payne J, Borganelli M, Saba S, Huang D, DiMarco J, Sichrovsky T, Kavesh N.

Author information

1
Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642-0653, USA. heartajm@heart.rochester.edu

Abstract

BACKGROUND:

The implantable cardioverter-defibrillator (ICD) is highly effective in reducing mortality among patients at risk for fatal arrhythmias, but inappropriate ICD activations are frequent, with potential adverse effects.

METHODS:

We randomly assigned 1500 patients with a primary-prevention indication to receive an ICD with one of three programming configurations. The primary objective was to determine whether programmed high-rate therapy (with a 2.5-second delay before the initiation of therapy at a heart rate of ≥200 beats per minute) or delayed therapy (with a 60-second delay at 170 to 199 beats per minute, a 12-second delay at 200 to 249 beats per minute, and a 2.5-second delay at ≥250 beats per minute) was associated with a decrease in the number of patients with a first occurrence of inappropriate antitachycardia pacing or shocks, as compared with conventional programming (with a 2.5-second delay at 170 to 199 beats per minute and a 1.0-second delay at ≥200 beats per minute).

RESULTS:

During an average follow-up of 1.4 years, high-rate therapy and delayed ICD therapy, as compared with conventional device programming, were associated with reductions in a first occurrence of inappropriate therapy (hazard ratio with high-rate therapy vs. conventional therapy, 0.21; 95% confidence interval [CI], 0.13 to 0.34; P<0.001; hazard ratio with delayed therapy vs. conventional therapy, 0.24; 95% CI, 0.15 to 0.40; P<0.001) and reductions in all-cause mortality (hazard ratio with high-rate therapy vs. conventional therapy, 0.45; 95% CI, 0.24 to 0.85; P=0.01; hazard ratio with delayed therapy vs. conventional therapy, 0.56; 95% CI, 0.30 to 1.02; P=0.06). There were no significant differences in procedure-related adverse events among the three treatment groups.

CONCLUSIONS:

Programming of ICD therapies for tachyarrhythmias of 200 beats per minute or higher or with a prolonged delay in therapy at 170 beats per minute or higher, as compared with conventional programming, was associated with reductions in inappropriate therapy and all-cause mortality during long-term follow-up. (Funded by Boston Scientific; MADIT-RIT ClinicalTrials.gov number, NCT00947310.).

PMID:
23131066
DOI:
10.1056/NEJMoa1211107
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center